Quarterly ResultMay 14, 2026, 08:36 AM
GRI Bio Phase 2a GRI-0621 IPF Data Shows Zero Cough, 60% Less Diarrhea
AI Summary
GRI Bio announced positive Phase 2a clinical trial data for GRI-0621 in idiopathic pulmonary fibrosis (IPF), showing zero cough and 60% less treatment-related diarrhea compared to placebo, alongside improved lung function. The company reported a net loss of $2.0 million for Q1 2026, with cash and equivalents totaling $11.0 million as of March 31, 2026. These funds are expected to support operations into Q2 2027, as GRI Bio advances GRI-0621 towards pivotal studies and GRI-0803 towards IND-enabling activities.
Key Highlights
- GRI-0621 Phase 2a showed zero cough in active arm vs 25% in placebo.
- GRI-0621 Phase 2a showed 61% reduction in diarrhea vs 33% in placebo.
- GRI-0621 Phase 2a showed +99 mL FVC improvement overall vs placebo.
- Cash and cash equivalents totaled $11.0 million as of March 31, 2026.
- Existing cash resources are expected to fund operations into Q2 2027.
- Net loss for Q1 2026 was $2.0 million, down from $3.0 million in Q1 2025.
- Generated $6.8 million gross proceeds from At The Market facility in Q1 2026.
- Advancing GRI-0803 toward IND-enabling activities for autoimmune diseases.